Do you need more information?
VIDAS® Troponin I Ultra, VIDAS® CK-MB and
VIDAS® Myoglobin* are automated quantitative assays for the assessment of myocardial damage.
Do you need more information?
The VIDAS® Acute Coronary Syndrome (ACS) panel offers three complementary tests for the assessment of myocardial injury1, 2. Performed on the instruments of the VIDAS® family, these assays are particularly suitable for emergency testing.
Cardiac Troponin I (cTnI) is an appreciated biomarker of cardiac necrosis due to its specificity for myocardial tissue damage2. An increase of cTnl levels (within 3 to 6 hours after the onset of chest pain) and the fact they remain elevated for 4 to 7 days3 give cTnI a good diagnostic value for myocardial infarction.
The protein concentration of the MB isoenzyme of human creatine kinase (CK-MB) also increases rapidly after infarction. Due to its shorter half-life, it can be used as a marker for re-infarction.
Myoglobin is one of the first markers of myocardial damage to be measured after the onset of myocardial infarction.
Temporal profile of cardiac necrosis markers after acute myocardial infarction
(adapted from [4]).
* Please consult our local subsidiary or representatives for the availability of these products in your country.
** Depending on local guidelines.
References:
VIDAS® Troponin I Ultra | VIDAS® CK-MB | VIDAS® Myoglobin | |
---|---|---|---|
Reference | 30448 | 30421 | 30446 |
Kit size | 60 tests | 30 tests | 30 tests |
Sample type | Serum, plasma (heparin) | Serum, plasma (heparin, EDTA) | Serum, plasma (heparin) |
Sample volume | 200 µL | 250 µL | 150 µL |
Calibration / Control Frequency | 28 days | 14 days | 14 days |
Time to result | 20 minutes | 30 minutes | 17 minutes |
Troponin I Ultra
CK-MB
Myoglobin
Please consult your local bioMérieux representative for product availability in your country
Links
[1] https://www.biomerieux-diagnostics.com/contact?pdt=241
[2] http://www.ncbi.nlm.nih.gov/pubmed/18230357
[3] http://www.ncbi.nlm.nih.gov/pubmed/23481696
[4] http://www.ncbi.nlm.nih.gov/pubmed/10683612
[5] http://www.ncbi.nlm.nih.gov/pubmed/12135685
[6] http://www.ncbi.nlm.nih.gov/pubmed/22922414
[7] http://www.ncbi.nlm.nih.gov/pubmed/21873419
[8] http://www.ncbi.nlm.nih.gov/pubmed/20685679
[9] http://www.ncbi.nlm.nih.gov/pubmed/22809746
[10] http://www.ncbi.nlm.nih.gov/pubmed/17384331
[11] http://www.escardio.org/Pages/index.aspx
[12] http://www.cardiosource.org/acc
[13] http://www.aacc.org/members/nacb/Pages/default.aspx
[14] https://www.biomerieux-diagnostics.com/emergency-department-patient-management
[15] https://www.biomerieux-diagnostics.com/acute-coronary-syndromes
[16] https://www.biomerieux-diagnostics.com/vidasr-high-sensitive-troponin-i
[17] https://www.biomerieux-diagnostics.com/vidasr-nt-probnp2-0
[18] https://www.biomerieux-diagnostics.com/vidasr-galectin-3-0
[19] https://www.biomerieux-diagnostics.com/vidasr-3
[20] https://www.biomerieux-diagnostics.com/mini-vidasr